Fig. 3: Validation and comparison of the nomogram-revised risk index (NRI). | Leukemia

Fig. 3: Validation and comparison of the nomogram-revised risk index (NRI).

From: Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

Fig. 3

The NRI was validated and compared with the international prognostic index (IPI), Ann Arbor staging, Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) models by the area under the curve (AUC) in the validation cohort. The AUC for predicting 5-year overall survival (OS) for all-stage (a) and early-stage (b) patients. The time-dependent AUC between 6 and 84 months for all-stage (c) and early-stage (d) patients.

Back to article page